Total Payments
$4,128
2024 Payments
$234.95
Companies
44
Transactions
245
Medicare Patients
1,946
Medicare Billing
$493,169
Payment Breakdown by Category
Food & Beverage$4,128 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,128 | 245 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $392.80 | 24 | $0 (2018) |
| SCILEX PHARMACEUTICALS INC. | $389.37 | 25 | $0 (2024) |
| Purdue Pharma L.P. | $310.20 | 18 | $0 (2018) |
| Depomed, Inc. | $276.46 | 20 | $0 (2017) |
| ABBVIE INC. | $229.90 | 12 | $0 (2024) |
| Assertio Therapeutics, Inc. | $223.37 | 15 | $0 (2020) |
| Medtronic Vascular, Inc. | $196.86 | 3 | $0 (2020) |
| PFIZER INC. | $188.69 | 12 | $0 (2021) |
| US WorldMeds, LLC | $165.01 | 13 | $0 (2019) |
| Abbott Laboratories | $137.65 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $234.95 | 11 | ABBVIE INC. ($140.85) |
| 2023 | $122.87 | 6 | AbbVie Inc. ($35.98) |
| 2022 | $53.07 | 3 | ABBVIE INC. ($53.07) |
| 2021 | $155.40 | 10 | SCILEX PHARMACEUTICALS INC. ($63.08) |
| 2020 | $485.97 | 28 | SCILEX PHARMACEUTICALS INC. ($153.17) |
| 2019 | $608.32 | 38 | US WorldMeds, LLC ($115.87) |
| 2018 | $862.80 | 50 | Daiichi Sankyo Inc. ($119.41) |
| 2017 | $1,604 | 99 | Depomed, Inc. ($276.46) |
All Payment Transactions
245 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/28/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $28.37 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/10/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $25.08 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 08/20/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $31.16 | General |
| Category: NEUROSCIENCE | ||||||
| 07/09/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: Analgesic | ||||||
| 06/05/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 05/23/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $26.64 | General |
| Category: OUD | ||||||
| 05/02/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $28.10 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 04/01/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $19.91 | General |
| Category: Analgesic | ||||||
| 02/21/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $25.39 | General |
| Category: PAIN MANAGEMENT | ||||||
| 01/26/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $3.14 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 01/26/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $1.31 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/30/2023 | AbbVie Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/08/2023 | AbbVie Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 06/05/2023 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $22.29 | General |
| Category: NEUROLOGY | ||||||
| 03/15/2023 | Almatica Pharma LLC | GRALISE (Drug) | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: POSTHERPETIC NEURALGIA | ||||||
| 02/28/2023 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Neuromodulation | ||||||
| 02/14/2023 | IBSA Pharma Inc. | LICART (Drug), TIROSINT, TIROSINT | Food and Beverage | Cash or cash equivalent | $19.04 | General |
| Category: non-opioid analgesic | ||||||
| 06/30/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: NEUROSCIENCE | ||||||
| 06/16/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: NEUROSCIENCE | ||||||
| 03/15/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: NEUROSCIENCE | ||||||
| 11/09/2021 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $13.24 | General |
| Category: Opioid Analgesic | ||||||
| 09/28/2021 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: Analgesic | ||||||
| 06/23/2021 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: Analgesic | ||||||
| 06/03/2021 | RedHill Biopharma Inc. | Movantik (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: Opioid Antagonist | ||||||
| 04/13/2021 | RedHill Biopharma Inc. | Movantik (Drug) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Opioid Antagonist | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 50 | 50 | $12,250 | $5,154 |
| 2022 | 2 | 580 | 1,267 | $310,310 | $133,701 |
| 2021 | 2 | 518 | 1,353 | $334,110 | $143,153 |
| 2020 | 8 | 798 | 2,142 | $487,610 | $211,160 |
Total Patients
1,946
Total Services
4,812
Medicare Billing
$493,169
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 25 | 25 | $8,750 | $3,688 | 42.1% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 25 | 25 | $3,500 | $1,467 | 41.9% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 290 | 633 | $221,550 | $95,554 | 43.1% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 290 | 634 | $88,760 | $38,147 | 43.0% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 260 | 689 | $241,150 | $103,474 | 42.9% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 258 | 664 | $92,960 | $39,679 | 42.7% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 347 | 951 | $332,850 | $144,182 | 43.3% |
| 80307 | Testing for presence of drug | Office | 2020 | 352 | 962 | $134,680 | $58,131 | 43.2% |
| 87798 | Detection test for organism | Office | 2020 | 11 | 141 | $6,345 | $4,849 | 76.4% |
| 93970 | Ultrasound scan of veins of both arms or legs including assessment of compression and functional maneuvers | Office | 2020 | 17 | 17 | $5,950 | $1,485 | 25.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 32 | 32 | $4,160 | $1,047 | 25.2% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 17 | 17 | $2,635 | $709.91 | 26.9% |
| 87640 | Detection test for staphylococcus aureus (bacteria) | Office | 2020 | 11 | 11 | $495.00 | $378.29 | 76.4% |
| 87641 | Detection test for staphylococcus aureus, methicillin resistant (mrsa bacteria) | Office | 2020 | 11 | 11 | $495.00 | $378.29 | 76.4% |
About Dr. Robert Thomas, MD
Dr. Robert Thomas, MD is a Physical Medicine & Rehabilitation healthcare provider based in Vestavia, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1134339799.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Thomas, MD has received a total of $4,128 in payments from pharmaceutical and medical device companies, with $234.95 received in 2024. These payments were reported across 245 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($4,128).
As a Medicare-enrolled provider, Thomas has provided services to 1,946 Medicare beneficiaries, totaling 4,812 services with total Medicare billing of $493,169. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Physical Medicine & Rehabilitation
- Other Specialties Pain Medicine
- Location Vestavia, AL
- Active Since 05/23/2007
- Last Updated 07/21/2022
- Taxonomy Code 208100000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1134339799
Products in Payments
- ZTLido (Drug) $258.32
- Movantik (Drug) $232.61
- Nucynta (Drug) $217.93
- Morphabond ER (Drug) $191.73
- BOTOX (Biological) $169.07
- Lucemyra/Lofexidine (Drug) $165.01
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $131.05
- Horizant (Drug) $127.31
- SPRIX (Drug) $122.34
- Proclaim Family of SCS IPGs (Device) $116.52
- LORZONE (Drug) $115.09
- Aimovig (Biological) $112.53
- LYRICA (Drug) $108.61
- Peripheral Orbital Atherectomy System (Device) $105.36
- Gralise (Drug) $96.96
- Zipsor (Drug) $94.73
- XTAMPZA (Drug) $80.23
- VIVLODEX (Drug) $79.31
- Cambia (Drug) $72.55
- HawkOne (Device) $67.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.